Drug firm to share raw trial data

摘要

The secrecy that has long surrounded drug-industry trials is crumbling. Scientists are applauding drug giant GlaxoSmithKline (GSK) for its announcement last week that it will make the trove of detailed raw data underlying its clinical trials systematically available to researchers. And GSK s move - the first such commitment for a big player in the industry - is just the beginning. Starting next year, the European Medicines Agency (EMA) intends to open up access to all new clinical-trial data sets it receives from industry for product registration.